CITIUS ONCOLOGY, INC. 8-K

What Happened

• On April 22, 2026, Citius Oncology, Inc. (Nasdaq: CTOR) announced it received a notice from Nasdaq saying the company's common stock had closed below the $1.00 minimum bid price for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
• Nasdaq has given the company a 180-calendar-day compliance period, through October 19, 2026, to regain compliance. The company’s shares remain listed on the Nasdaq Capital Market and the notice does not have any immediate effect on the listing.

Key Details

• Notification date: April 22, 2026.
• Rule cited: Nasdaq Listing Rule 5550(a)(2) (minimum $1.00 bid price).
• Cure period: 180 calendar days (until October 19, 2026); compliance is achieved if the bid closes at $1.00+ for at least 10 consecutive business days.
• If not cured, the company may be eligible for a second 180-day period if it meets market-value and other initial listing standards (except the bid-price rule) and provides written notice to effect a reverse stock split if needed. The company may appeal any delisting determination to a Nasdaq hearings panel.

Why It Matters

• This notice signals a risk of delisting if the stock price does not recover, which can affect liquidity, investor access, and institutional interest.
• For now, CTOR remains listed and tradable; investors should watch the stock price and company updates because failure to regain compliance could trigger a delisting process or require corporate actions (e.g., a reverse split) to remain on Nasdaq.